We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Biofusion | LSE:BFN | London | Ordinary Share | GB00B05L5X50 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 86.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number : 3520A Biofusion PLC 31 July 2008 For immediate release 31 July 2008 BIOFUSION PLC Result of General Meeting and Name Change to Fusion IP Biofusion plc (AIM: BFN), the university IP commercialisation company that turns world class university research into business, is pleased to announce that at the Group's General Meeting (GM) held earlier today, all resolutions were duly passed. The GM was held in relation to the expansion of the Group's 10 year exclusive agreement with the University of Sheffield to include the commercialisation of all non-life science research-generated intellectual property and the Group's £2.115 million fundraising, as announced on 7 July 2008. It is expected that admission of the 5,489,999 New Ordinary Shares to the London Stock Exchange will become effective and dealings in these New Ordinary Shares will commence at 8am tomorrow, 1 August 2008. As a result of the resolutions being passed, and following the registration of the name at Companies House expected later today, the Group's name will be changed from Biofusion plc to Fusion IP plc to reflect more accurately the Group's enlarged business which now includes IP in areas such as energy, engineering and electronics. Additionally, the Company is changing its ticker to "FIP" and its classification from "Pharmaceuticals and Biotechnology" to "General Financial". These changes are expected to become effective from 1 August 2008. For further information please contact: Biofusion +44 (0)114 275 5555 David Baynes, Chief Executive Officer Stuart Gall, Commercial Director Nomura Code Securities +44 (0) 20 7776 1200 Phil Walker Buchanan Communications +44 (0)20 7466 5000 Mary-Jane Johnson / Lisa Baderoon / Catherine Breen This information is provided by RNS The company news service from the London Stock Exchange END MSCSDEFDFSASEFW
1 Year Biofusion Chart |
1 Month Biofusion Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions